This group has a Zacks Industry Rank of 240, putting it in the bottom 6% of all 250+ industries. The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. Beam Global is currently a Zacks Rank #3 (Hold). The Zacks Consensus EPS estimate has moved 9.17% lower within the past month. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Our research shows that these estimate changes are directly correlated with near-term stock prices. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. These revisions help to show the ever-changing nature of near-term business trends. Investors should also note any recent changes to analyst estimates for Beam Global. These totals would mark changes of +10.81% and +92.85%, respectively, from last year. With a historical volatility rate of 81.90%, the RSI 9-day stood at 41.78% on 17 August.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.66 per share and revenue of $17.36 million. This quick technical analysis looks at Beam Therapeutics Inc.’s (BEAM) price momentum. The value of shareholders’ equity is $70.36 million. were 618.21 million at the end of its most recent quarter ended June 29, and its total debt was $177.67 million. Tip: Click on a gray bar for that chart’s description. In addition to the latest Beam Global (BEEM) stock price, this page includes 7 charts that add a unique perspective to the latest stock quote. The liabilities of Beam Therapeutics Inc. BEEM Stock Price Today (plus 7 insightful charts) Menu Live 1yr 2000 Volatility RS Avg Year Avg Day. During the quarter, the company generated -$79.25 million in EBITDA. to report -$1.08 quarterly earnings, the actual figure was -$1.02 per share, beating the consensus estimate by 5.60%. While analysts expected Beam Therapeutics Inc. BEAM’s revenue rose 99.94% to $8.43 million during the quarter, while net income inched up to $16.65 million. Return on equity (ROE) for the past 12 months was -28.30%.Īccording to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. In the past year, return on investment (ROI) was -47.20%. Based on annual data, BEAM earned $51.84 million in gross profit and brought in $51.84 million in revenue.Ī company’s management is another factor that investors consider when determining the profitability of an investment. In the three months ended June 29, Beam Therapeutics Inc.’s quick ratio stood at 5.60, while its current ratio was 5.60, showing that the company is able to pay off its debt. The latest dividend of $0.2250 per share was paid out, remained unchanged from last year’s $0.2250. The transaction was valued at $1,972,523. The insider now owns 123,000 shares following the transaction. sold 20,000 shares at an average price of $65.78 on Jul 28. It resulted in a $1,229,806 divestment by the insider. FMR LLC, the See Remark 1 of the company, disposed of 20,326 shares for $60.50 on Aug 05. (BEAM) last reported insider trading activity 13 days ago on Aug 05. We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.Ĭlick here for full details and to join for free.īeam Therapeutics Inc. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential. He buys up valuable assets when they are very cheap. The world's greatest investor - Warren Buffett - has a simple formula for making big money in the markets.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |